SAN DIEGO, Aug. 12, 2014 /PRNewswire-iReach/ -- eLux Medical, Inc., developer of NanoLipo™, a novel nanomedicine approach to liposuction, is pleased to announce that Professor Robert S. Langer, Sc.D., has joined its Scientific Advisory Board. Dr. Langer is the David H. Koch Institute Professor at the Massachusetts Institute of Technology. Dr. Langer has written over 1,250 articles and has over 1,060 patents worldwide, many of which have been licensed or sublicensed to over 250 pharmaceutical, chemical, biotechnology and medical device companies. (a full biography for Dr. Langer is available at web.mit.edu/langerlab/langer.html.)
Dr. Langer stated: "NanoLipo is a very novel approach to making liposuction a more consistent and successful procedure for both physicians and their patients. I am very pleased to be asked to contribute to its development."
Dr. Langer will advise eLux as it prepares for the clinical trial phase of the development of NanoLipo, a proprietary injectable solution of gold nanoparticles which is projected to transform the performance and results of liposuction, the number one cosmetic surgery worldwide.
eLux co-Founder and Chief Technology Officer, Professor Adah Almutairi, Ph.D., said: "the pre-clinical results of NanoLipo have been very encouraging. As we move into clinical trials, we are honored to have Dr. Langer join our Scientific Advisory Board. His extensive experience and advice will be invaluable throughout our technical development and commercialization process."
About eLux Medical, Inc.
San Diego based eLux Medical is a development stage company, which has spun out of the University of California San Diego (UCSD) Center of Excellence in Nanomedicine, of which Professor Adah Almutairi is the Director. eLux Medical has an exclusive worldwide license on the intellectual property related to NanoLipo from UCSD.
About Forward-Looking Statements
The Company cautions you that the statements included in the press release that are not a description of historical facts are forward-looking statements. These include statements regarding the potential clinical benefits of NanoLipo and the commercial prospects of eLux Medical, Inc. NanoLipo is an investigational device and is not approved for sale in the USA or any other country.
John R. Lyon, CEO
Media Contact: Chris Smith, eLux Medical Inc,, 858-220-6939, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
|SOURCE eLux Medical Inc.|
Copyright©2014 PR Newswire.
All rights reserved